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Backgorund: The aim of this study was to evaluate dysphagia in patients with head and neck cancer (HNC)
undergoing three-dimensional conformal radiation therapy using objective and subjective tools simultaneously and
to associate the clinical correlates of dysphagia with dosimetric parameters.
Methods: Twenty patients were included in the study. The primary tumor and the involved lymph nodes (LN) were
treated with 66-70 Gy, the uninvolved LN were treated with 46-50 Gy. Six swallowing structures were identified: the
superior pharyngeal constrictor muscle (SPCM), the middle pharyngeal constrictor muscle (MPCM), the inferior
pharyngeal constrictor muscle (IPCM), the base of tongue (BOT), the larynx and the proximal esophageal sphincter
(PES). Dysphagia was evaluated using videofluoroscopy and European Organization for Research and Treatment of
Cancer (EORTC) QoL questionnaire (QLQ-C30) and supplemental EORTC QoL module for HNC (QLQ-H&N35). The
evaluations were performed before treatment, at 3 months and at 6 months following treatment.
Results: On objective evaluation, the Dmax for the larynx and the sub-structures of the PCM were correlated with
impaired lingual movement, BOT weakness and proximal esophageal stricture at 3 months, whereas the V65, the
V70and the Dmax for the larynx was correlated with BOT weakness and the V65, the V70, the Dmax or the Dmean for
the sub-structures of the PCM were correlated with impaired lingual movement, BOT weakness, reduced laryngeal
elevation, reduced epiglottic inversion and aspiration at 6 months following treatment. On subjective evaluation,
the V60, the Dmax and the Dmean for SPCM were correlated with QoL scores for HNSO at 3 months, whereas the V70
for SPCM were correlated with QoL scores for HNPA and the V60, the V65, the V70, the Dmax and the Dmean for SPCM
were correlated with QoL scores for HNSO at 6 months following treatment.
Conclusions: The use of multiple dysphagia-related endpoints to complement eachother rather than to overlap
with one another, as well as the use of multiple evaluations over time to represent a scale of early to late findings
might provide a better insight in terms of the association of the clinical correlates of dysphagia with the
dose-volume data for the dysphagia-related anatomical structures.
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For head and neck cancer (HNC), the intensification of
radiation therapy through the use of altered fractionation
schedules and/or concomitant chemotherapy has resulted
in significantly improved local control and survival rates.
However, these intensified regimens are associated with
increased rates of early as well as late dysphagia with
presumably prolonged duration [1-3]. Patients with HNC
might experience dysphagia either due to their disease or
as a consequence of their treatment. Dsyphagia following
radiation therapy for HNC might have a significant detri-
mental effect on the quality-of-life (QoL) [4]. Besides dys-
phagia, the intensified regimens might be associated with
laryngeal edema that promotes aspiration and an increased
risk of pneumonia. The recognition of the association
between the intensification of the treatment regimens
and the worsening of dysphagia has led to the evalu-
ation of the correlations between dysphagia and the
dose-volume data for the swallowing-related structures,
exploiting the possibility of minimizing the dose deliv-
ered to these structures [5-7].
An intrinsic problem associated with such evaluations is
the lack of a consensus regarding the timing of dysphagia,
since it can be evaluated either as an acute toxicity or as a
late toxicity, as well as the definition of dysphagia, since it
can be evaluated either objectively through invasive tech-
niques such as videofluoroscopy (VF) and fiberoptic endo-
scopic evaluation of swallowing (FEES) or subjectively
through several specific validated QoL questionnaires, as a
treatment related toxicity end point [3]. Hence, the aim of
this study was to evaluate both early and late dysphagia in
patients with HNC undergoing three-dimensional con-
formal radiation therapy (3DCRT) using objective and
subjective tools simultaneously and to associate the clin-
ical correlates of dysphagia with dosimetric parameters.
Materials and method
The study design was approved by the Institutional Review
Board of Kocaeli University and all of the patients were
required to provide written informed consent regarding
their participation in the study. Twenty patients with
HNC who would receive definitive treatment with 3DCRT
with or without concomitant chemotherapy were included
in the study. There were 17 males and three females. Their
ages ranged from 30 to 76 years (median, 63 years).
Tumor localization was the nasopharynx in 10 patients
and the supraglottic larynx in 10 patients. Twelve patients
received concomitant chemotherapy whereas eight pa-
tients did not receive concomitant chemotherapy.
Treatment
The patient was placed in the supine position and the
head was immobilized with a customized thermoplastic
mask. The neck was extended and the shoulders wererelaxed downward with gentle traction. For radiation
therapy planning purposes, computed tomography (CT)
images from the vertex to below the clavicles were ob-
tained with a 16-slice scanner using a slice thickness of
3 mm. Intravenous contrast was not used. Radiation ther-
apy was delivered through parallel-opposed lateral portals
encompassing the primary tumor and the cervical lymph
nodes, matched with an anterior portal encompassing the
supraclavicular lymph nodes. The primary tumor was
treated with 70 Gy, the involved cervical lymph nodes
were treated with 66 to 70 Gy (median, 70 Gy), the unin-
volved cervical lymph nodes were treated with 50 to
60 Gy (median, 60 Gy) and the supraclavicular lymph
nodes were treated with 46 to 50 Gy (median, 50 Gy)
using daily fractions of 2 Gy.
Evaluation of dose-volume data
The planning CT images and the 3DCRT plans were
retrieved from the treatment planning system (XiO, CMS
Inc., St. Louis, MO, USA) for the retrospective delineation
of the swallowing structures at risk and the respective dose
versus volume analysis using dose-volume histograms
(DVH). Based on a literature search, six swallowing struc-
tures were identified: the superior pharyngeal constrictor
muscle (SPCM), the middle pharyngeal constrictor muscle
(MPCM), the inferior pharyngeal constrictor muscle
(IPCM), the base of tongue (BOT), the larynx and the prox-
imal esophageal sphincter (PES). The mean dose (Dmean)
and the maximum dose (Dmax) to each of these structures
and the partial volumes of each of these structures receiving
a specified dose (VDS) were calculated from the DVHs
(Table 1, Table 2 and Table 3). The maximum dose was
defined as the dose received by 0.1 cc of the respective
structure.
Evaluation of dysphagia
Dysphagia was evaluated objectively using VF and subject-
ively using the European Organization for Research and
Treatment of Cancer (EORTC) QoL questionnaire (QLQ-
C30) and the supplemental EORTC QoL module for HNC
(QLQ-H&N35). The evaluations were performed before
treatment, at 3 months following treatment and at 6 months
following treatment.
Videofluoroscopy
For VF, the patient was seated and viewed in the lateral
plane and the anteroposterior plane for images of the lips
anteriorly, the cervical vertebra posteriorly, the soft palate
superiorly and the lower end of the cervical esophagus
inferiorly. The patient was asked to swallow thin liquid
barium (diluted with water) followed with non-diluted
barium. A timer was activated at the start of the examin-
ation and the examination was monitored and recorded
for the evaluation to be completed subsequently. The
Table 1 The mean dose (Dmean) and the maximum dose (Dmax) to each of the swallowing structures and the partial volumes of each of these structures
receiving a specified dose (VDS) as calculated from the dose-volume histograms (DVH) for the entire group of patients
Dose-volume data
Swallowing structure Dmean (Gy) Mean ± SD (range) Dmax (Gy) Mean ± SD (range) V60 (%) Mean ± SD (range) V65 (%) Mean ± SD (range) V70 (%) Mean ± SD (range)
PCM 61.96 ± 7.90 (33.26 - 69.96) 72.61 ± 2.55 (64.88 - 76.79) 74.57 ± 19.83 (31.00 - 99.92) 51.31 ± 24.47 (0.00 - 90.38) 22.24 ± 19.50 (0.00 - 65.33)
SPCM 60.66 ± 11.85 (22.94 - 71.65) 70.55 ± 4.56 (58.34 - 76.79) 70.83 ± 34.87 (0.00 - 100.00) 49.13 ± 41.45 (0.00 - 100.00) 22.23 ± 28.19 (0.00 - 83.03)
MPCM 66.65 ± 3.51 (61.28 - 74.03) 69.63 ± 3.72 (63.47 - 76.79) 98.23 ± 4.79 (79.56 - 100.00) 61.56 ± 42.23 (0.00 - 100.00) 22.97 ± 37.04 (0.00 - 100.00)
IPCM 63.58 ± 6.06 (50.39 - 71.55) 68.61 ± 4.30 (61.27 - 75.99) 75.83 ± 31.97 (2.35 - 100.00) 46.90 ± 45.55 (0.00 - 100.00) 16.51 ± 29.57 (0.00 - 88.40)
BOT 50.75 ± 12.52 (23.71 - 71.49) 69.39 ± 4.90 (53.82 - 74.83) 49.38 ± 31.76 (0.00 - 99.99) 27.05 ± 30.75 (0.00 - 99.97) 8.38 ± 18.41 (0.00 - 77.40)
Larynx 66.84 ± 6.37 (50.56 - 74.89) 72.64 ± 4.00 (64.45 - 79.30) 87.11 ± 23.21 (29.27 - 100.00) 69.66 ± 33.84 (0.00 - 100.00) 39.25 ± 40.02 (0.00 - 100.00)
PES 50.48 ± 9.83 (25.41 - 66.83) 59.63 ± 7.65 (47.11 - 69.85) 17.45 ± 27.58 (0.00 - 100.00) 10.43 ± 23.51 (0.00 - 99.32) 0.00
The pharyngeal constrictor muscle: PCM, the superior pharyngeal constrictor muscle: SPCM, the middle pharyngeal constrictor muscle: MPCM, the inferior pharyngeal constrictor muscle: IPCM, the base of tongue:

















Table 2 The mean dose (Dmean) and the maximum dose (Dmax) to each of the swallowing structures and the partial volumes of each of these structures
receiving a specified dose (VDS) as calculated from the dose-volume histograms (DVH) for patients with nasopharyngeal primaries
Dose-volume data
Swallowing structure Dmean (Gy) Mean ± SD (range) Dmax (Gy) Mean ± SD (range) V60 (%) Mean ± SD (range) V65 (%) Mean ± SD (range) V70 (%) Mean ± SD (range)
PCM 66.03 ± 2.19 (63.17 - 69.96) 72.69 ± 1.62 (69.92 - 74.85) 89.24 ± 9.20 (73.27 - 99.92) 64.75 ± 22.79 (20.19 - 90.38) 27.91 ± 21.83 (0.00-65.33)
SPCM 68.35 ± 2.66 (63.29 - 71.65) 72.66 ± 1.64 (69.92 - 74.85) 99.14 ± 1.64 (94.98 - 100.00) 81.35 ± 26.41 (24.37 - 100.00) 37.66 ± 30.09 (0.00-83.03)
MPCM 65.30 ± 2.77 (61.28 - 69.62) 67.69 ± 2.60 (64.23 - 72.03) 97.63 ± 6.43 (79.56 - 100.00) 51.33 ± 45.38 (0.00 - 100.00) 4.80 ± 11.93 (0.00-37.40)
IPCM 59.96 ± 4.09 (50.39 - 63.35) 65.86 ± 3.18 (61.27 - 71.83) 58.50 ± 34.43 (2.35 - 100.00) 12.09 ± 19.33 (0.00-48.71) 0.62 ± 1.97 (0.00-6.22)
BOT 52.85 ± 13.03 (36.80 - 68.08) 70.02 ± 2.79 (65.36 - 74.00) 62.38 ± 32.78 (15–99.55) 34.12 ± 31.63 (0.01-90.03) 5.54 ± 11.05 (0.00-34.86)
Larynx 62.55 ± 5.76 (50.56 - 68.07) 70.43 ± 2.97 (64.45 - 73.54) 74.92 ± 28.33 (29.27 - 100.00) 52.05 ± 31.83 (0.00-89.83) 9.52 ± 12.30 (0.00-32.72)
PES 50.97 ± 3.22 (46.09 - 57.15) 53.78 ± 4.76 (47.11 - 61.75) 2.08 ± 4.40 (0.00 - 11.10) 0.00 0.00
The pharyngeal constrictor muscle: PCM, the superior pharyngeal constrictor muscle: SPCM, the middle pharyngeal constrictor muscle: MPCM, the inferior pharyngeal constrictor muscle: IPCM, the base of tongue:

















Table 3 The mean dose (Dmean) and the maximum dose (Dmax) to each of the swallowing structures and the partial volumes of each of these structures
receiving a specified dose (VDS) as calculated from the dose-volume histograms (DVH) for patients with laryngeal primaries
Dose-volume data
Swallowing structure Dmean (Gy) Mean ± SD (range) Dmax (Gy) Mean ± SD (range) V60 (%) Mean ± SD (range) V65 (%) Mean ± SD (range) V70 (%) Mean ± SD (range)
PCM 57.89 ± 9.49 (33.26 - 67.07) 72.53 ± 3.33 (64.88 – 76.79) 59.91 ± 16.35 (31.00 – 82.97) 37.87 ± 18.54 (0.00 – 70.75) 16.58 ± 15.97 (0.00 – 40.19)
SPCM 52.97 ± 12.57 (22.94 – 68.71) 68.46 ± 5.61 (58.34 – 76.79) 42.52 ± 27.99 (0.00 – 90.38) 16.92 ± 24.95 (0.00 – 90.38) 16.92 ± 24.95 (0.00 – 84.11)
MPCM 67.70 ± 3.78 (62.41 – 74.03) 71.58 ± 3.74 (63.47 – 76.79) 98.84 ± 2.51 (93.06 – 100.00) 71.79 ± 38.37 (0.00 – 100.00) 41.15 ± 44.95 (0.00 – 100.00)
IPCM 68.20 ± 3.64 (61.52 – 71.55) 71.35 ± 3.48 (63.32 – 75.99) 93.15 ± 17.48 (44.84 – 100.00) 81.71 ± 36.25 (0.00 – 100.00) 32.39 ± 35.80 (0.00 – 88.40)
BOT 48.65 ± 12.29 (23.71 – 71.49) 68.75 ± 6.49 (53.82 – 74.83) 36.37 ± 26.09 (0.00 – 99.99) 19.99 ± 29.75 (0.00 – 99.97) 11.21 ± 23.99 (0.00 – 77.40)
Larynx 71.13 ± 3.34 (64.16 – 74.89) 74.85 ± 3.75 (66.42 – 79.30) 99.30 ± 2.03 (93.54 – 100.00) 87.27 ± 26.73 (20.00 – 100.00) 68.98 ± 35.57 (0.00 – 100.00)
PES 49.99 ± 13.89 (25.41 – 66.83) 65.48 ± 4.97 (55.77 – 69.85) 32.83 ± 32.58 (0.00 – 100.00) 20.86 ± 30.41 (0.00 – 99.32) 0.00
The pharyngeal constrictor muscle: PCM, the superior pharyngeal constrictor muscle: SPCM, the middle pharyngeal constrictor muscle: MPCM, the inferior pharyngeal constrictor muscle: IPCM, the base of tongue:
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http://www.ro-journal.com/content/9/1/137examination was interpreted separately by two radiologists
regarding the manipulation, the control and the passage of
the bolus, with the focus on cohesion, motility and timing.
Impaired lingual movement, BOT weakness, pharyngeal
residue, reduced laryngeal elevation, reduced epiglottic in-
version, swallow reflex delay, cricopharyngeal muscle (CM)
dysfunction, proximal esophageal stricture, penetration
and aspiration were evaluated under VF (Table 4). Im-
paired lingual movement was defined as rolling move-
ments of the tongue with repetitive attempts at initiating
swallowing, resulting in some portion of the bolus
remaining in the mouth. BOT weakness was defined as the
loss of contact of the base of tongue with the posterior
pharyngeal wall due to reduced motion and the resultant
worsening of the propulsion of the bolus. Pharyngeal resi-
due was defined as any portion of the bolus remaining in
the vallecula or the pyriform sinuses after the swallow, with
the potential risk of aspiration after the swallow. Reduced
laryngeal elevation was determined by measuring the ex-
tent of maximal laryngeal rise during swallow. Reduced
epiglottic inversion was defined as the diminished degree
of movement of the epiglottis from vertical to horizontal
during swallowing. Swallow reflex delay was defined as the
duration of the swallowing phase beyond the range found
in normal controls. CM dysfunction was defined as the in-
dentation of the CM into the lumen of the hypopharynx,
incomplete relaxation and premature closure. Proximal
esophageal stricture was defined based on the size of the
narrowest point of opening of the PES during maximal dis-
tention in the proximal esophagus for bolus passage. Pene-
tration was defined as any portion of the bolus entering
the laryngeal vestibule to the level of (but not passing
below) the vocal folds. Aspiration was defined as occurring
once the bolus passed the level of the vocal folds and
entered the subglottic region.Table 4 The videofluoroscopy findings regarding impaired lin
pharyngeal residue, reduced laryngeal elevation, reduced ep
muscle (CM) dysfunction, proximal esophageal stricture, pene
following treatment and at 6 months following treatment
Videofluoroscopy finding Before treatment n (%) At 3 months
Impaired lingual movement 1 (5)
BOT weakness 10 (50)
Pharyngeal residue 7 (35)
Reduced laryngeal elevation 2 (10)
Reduced epiglottic inversion 0 (0)
Swallow reflex delay 0 (0)
CM dysfunction 0 (0)
Proximal esophageal stricture 3 (15)
Penetration 5 (25)
Aspiration 0 (0)Quality-of-life
The patient was asked to independently fill in the Turkish
translation of the EORTC QLQ-C30 (Version 3.0) consist-
ing of 30 items and the supplemental EORTC QLQ-
H&N35 consisting of 35 items. The EORTC QLQ-C30 [8]
was used to evaluate the general QoL using the global
health status/QoL (QL) constructed scale, whereas the
EORTC QLQ-H&N35 [9] was used to evaluate the
dysphagia-related QoL using the pain (HNPA), the swal-
lowing (HNSW) and the trouble with social eating (HNSO)
symptom scales (Table 5). Regarding the EORTC QLQ-
C30, the higher scores represented better responses in
terms of the general QoL, whereas regarding the EORTC
QLQ-H&N35, the lower scores represented better re-
sponses in terms of the dysphagia-related QoL.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 17.0 (SPSS Inc., 2008, Chicago, USA).
McNemar’s test was used to compare VF findings and
paired samples t-test was used to compare QoL scores.
Mann–Whitney U test was used to correlate dose-
volume data and QoL scores with VF findings. Pearson
product–moment correlation was used to correlate
dose-volume data with QoL scores. Statistical signifi-
cance was considered when the p-value was 0.05 and
below.
Results
Objective evaluation of dysphagia using VF
The difference in terms of the VF finding of reduced
epiglottic inversion before treatment as compared to that
finding at 3 months following treatment was statistically
significant (p = 0.03). The difference in terms of the VF
finding of penetration before treatment as compared togual movement, base of tongue (BOT) weakness,
iglottic inversion, swallow reflex delay, cricopharyngeal
tration and aspiration before treatment, at 3 months
Evaluation period
following treatment n (%) At 6 months following treatment n (%)
4 (20) 2 (10)
15 (75) 12 (60)
11 (55) 10 (50)
2 (10) 3 (15)
6 (30) 5 (25)
1 (5) 1 (5)
2 (10) 2 (10)
5 (25) 6 (30)
10 (50) 14 (70)
1 (5) 4 (20)
Table 5 The quality-of-life (QoL) scores regarding the general QoL using the global health status/QoL (QL) constructed scale
and the dysphagia-related QoL using the pain symptom scale (HNPA), the swallowing symptom scale (HNSW) and the
trouble with social eating symptom scale (HNSO) at 3 months following treatment and at 6 months following treatment
Evaluation period
QoL score Before treatment
Mean ± SD (range)
At 3 months following treatment
Mean ± SD (range)
At 6 months following treatment
Mean ± SD (range)
QL 65 ± 24 (17–20) 67 ± 15 (33–83) 66 ± 19 (17–92)
HNPA 18 ± 24 (0–75) 17 ± 28 (0–100) 12 ± 19 (0–58)
HNSW 21 ± 20 (0–58) 36 ± 21 (0–100) 34 ± 24 (0–100)
HNSO 21 ± 22 (0–75) 33 ± 28 (0–100) 33 ± 30 (0–92)
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cally significant (p = 0.004). There was no statistically
significant difference when the patients were grouped
according their tumor localization (the nasopharynx ver-
sus the supraglottic larynx) or the chemotherapy status
(receiving concomitant chemotherapy versus not receiving
concomitant chemotherapy).
Subjective evaluation of dysphagia using QLQ-C30 and
QLQ-H&N35
The difference in terms of the HNSW scores before
treatment as compared to those scores at 3 months fol-
lowing treatment was statistically significant (p = 0.05).
There was no statistically significant difference when the
patients were grouped according their tumor localization
or the chemotherapy status.
Dose-volume data correlated with VF findings
When compared according the presence of impaired lin-
gual movement on VF, the difference in terms of Dmax
(69.66 vs 74.15 Gy, p = 0.05) for SPCM at 3 months
following treatment and the difference in terms of V70
(15.88 vs 86.78%, p = 0.04) for MPCM at 6 months
following treatment were statistically significant. When
compared according the presence of BOT weakness on
VF, the difference in terms of Dmax (69.24 vs 73.77 Gy,
p = 0.03) at 3 months following treatment and in terms
of V65 (54.43 vs 79.82%, p = 0.03), V70 (12.82 vs 56.87%,
p = 0.02) and Dmax (70.26 vs 74.22 Gy, p = 0.03) at
6 months following treatment for the larynx, the differ-
ence in terms of V70 (11.66 vs 30.51%, p = 0.04), Dmean
(64.65 vs 67.98 Gy, p = 0.03) and Dmax (67.49 vs
71.06 Gy, p = 0.03) for MPCM at 6 months following
treatment and the difference in terms of V65 (15.53 vs
67.81%, p = 0.005), Dmean (59.97 vs 65.99 Gy, p = 0.03)
and Dmax (65.76 vs 70.51 Gy, p = 0.02) for IPCM at
6 months following treatment were statistically signifi-
cant. When compared according the presence of re-
duced laryngeal elevation on VF, the difference in terms
of V65 (41.06 vs 94.85%, p = 0.05) at 6 months following
treatment for SPCM and the difference in terms of V65
(46.31 vs 79.64%, p = 0.04) at 6 months followingtreatment for PCM were statistically significant. When
compared according the presence of reduced epiglottic
inversion on VF, the difference in terms of V70 (12.48 vs
51.47%, p = 0.01) and Dmax (69.53 vs 73.62 Gy, p = 0.05)
at 6 months following treatment for SPCM and the
difference in terms of V70 (15.84 vs 41.45%, p = 0.01) and
Dmean (60.85 vs 65.30 Gy, p = 0.05) at 6 months follow-
ing treatment for PCM were statistically significant.
When compared according the presence of proximal
esophageal stricture on VF, the difference in terms of
V70 (8.74 vs 39.79%, p = 0.04) and Dmax (67.59 vs
71.66 Gy, p = 0.05) at 3 months following treatment for
IPCM were statistically significant. When compared ac-
cording the presence of aspiration on VF, the difference
in terms of V70 (14.09 vs 58.51%, p = 0.05) and Dmean
(65.80 vs 70.04 Gy, p = 0.05) at 6 months following treat-
ment for MPCM were statistically significant.
For patients with nasopharyngeal primaries, when
compared according the presence of impaired lingual
movement on VF, the difference in terms of Dmean
(61.26 vs 67.74 Gy, p = 0.04) for larynx at 3 months
following treatment was statistically significant. When
compared according the presence of BOT weakness on
VF, the difference in terms of Dmax (65.64 vs 68.56 Gy,
p = 0.05) for MPCM, Dmax (62.92 vs 67.12 Gy, p = 0.03)
for IPCM, V70 (0 vs 13.6%, p = 0.02) and Dmax (66.77 vs
72.00 Gy, p = 0.02) for larynx at 3 months and interms
of Dmean (2.93 vs 66.31 Gy, p = 0.03) and Dmax (65.64 vs
68.56 Gy, p = 0.02) for MPCM, Dmax (62.92 vs 67.12 Gy,
p = 0.01) for IPCM, V70 (0 vs 13.6 Gy, p = 0.01) and Dmax
(66.77 vs 72.00 Gy, p = 0.01) for larynx at 6 months
following treatment were statistically significant. When
compared according the presence of reduced laryngeal
elevation on VF, the difference in terms of V70 (4.41 vs
29.96%, p = 0.03) for larynx at 3 months and in terms of
V70 (0 vs 15.99%, p = 0.02) and Dmax (66.61 vs 70.18 Gy,
p = 0.05) for MPCM, Dmax (64.45 vs 69.15 Gy, p = 0.03)
for IPCM, V70 (3.31 vs 24.00%, p = 0.03) and Dmax (69.36
vs 72.93 Gy, p = 0.02) for larynx at 6 months following
treatment were statistically significant. When compared
according the presence of reduced epiglottic inversion
on VF, the difference in terms of V70 (14.93 vs 47.38%,
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PCM, V70 (20.90 vs 62.80%, p = 0.05) for SPCM at
6 months following treatment were statistically signifi-
cant. When compared according the presence of prox-
imal esophageal stricture on VF, V70 (0 vs 3.11%, p =
0.05) for IPCM and Dmax (69.71 vs 73.32 Gy, p = 0.04)
for larynx at 3 months following treatment and in terms
of Dmax (64.69 vs 68.58Gy, p = 0.05) for IPCM and Dmax
(69.36 vs 72.93 Gy, p = 0.03) for larynx at 6 months
following treatment were statistically significant. When
compared according the presence of aspiration on VF,
Dmean (65.98 vs 66.26%, p = 0.04) for PCM, V70 (0 vs
3.11%, p = 0.05) for IPCM and Dmax (69.71 vs 73.32 Gy,
p = 0.05) for larynx at 6 months following treatment
were statistically significant.
For patients with laryngeal primaries, when compared
according the presence of impaired lingual movement
on VF, the difference in terms of V70 (6.21 vs 9.14%, p =
0.05) and Dmax (66.88 vs 74.78 Gy, p = 0.05) for SPCM,
V70 (26.85 vs 98.32%, p = 0.03), Dmean (66.79 vs
72.83 Gy, p = 0.04) and Dmax (70.58 vs 75.56 Gy, p =
0.04) for MPCM at 3 months following treatment were
statistically significant. When compared according the
presence of proximal esophageal stricture on VF, the dif-
ference in terms of Dmean (67.09 vs 70.78 Gy, p = 0.05)
for IPCM at 3 months and interms of Dmean (67.09 vs
70.78 Gy, p = 0.05) for IPCM at 6 months following treat-
ment were statistically significant. When compared ac-
cording the presence of penetration on VF, the difference
in terms of Dmax (64.44 vs 71.14 Gy, p = 0.05) for SPCM at
6 months following treatment were statistically significant.
When compared according the presence of aspiration on
VF, the difference in terms of V70 (6.21 vs 9.14%, p = 0.05)
and Dmax (66.88 vs 74.78 Gy, p = 0.05) for SPCM at
6 months following treatment were statistically significant.
For patients receiving chemotherapy, when compared
according the presence of BOT weakness on VF, the dif-
ference in terms of V60 (92.10 vs 99.23%, p = 0.05), V65
(18.80 vs 70.27%, p = 0.05), V70 (0 vs 21.40%, p = 0.05),
Dmean (62.93 vs 67.50 Gy, p = 0.05) and Dmax (65.64 vs
71.30 Gy, p = 0.01) for MPCM, V65 (0 vs 67.47%, p =
0.01), V70 (0 vs 32.82%, p = 0.05), Dmean (56.32 vs
65.80 Gy, p = 0.05) and Dmax (62.92 vs 71.27 Gy, p =
0.01) for IPCM, V65 (31.74 vs 80.64%, p = 0.05), V70 (0 vs
54.34%, p = 0.01) and Dmax (66.77 vs 74.44 Gy, p = 0.01)
for larynx at 3 months and interms of V65 (20.12 vs
84.03%, p = 0.01), V70 (0 vs 27.52%, p = 0.009), Dmean
(63.42 vs 68.46 Gy, p = 0.007) and Dmax (66.46 vs
72.33 Gy, p = 0.004) for MPCM, Dmax (65.23 vs
72.00 Gy, p = 0.03) for IPCM, V70 (11.74 vs 61.47%, p =
0.02) and Dmax (69.17 vs 74.91 Gy, p = 0.02) for larynx at
6 months following treatment were statistically signifi-
cant. When compared according the presence of re-
duced epiglottic inversion on VF, the difference in termsof V70 (20.38 vs 51.54%, p = 0.01) and Dmean (63.01 vs
68.18 Gy, p = 0.02) for PCM, V70 (14.06 vs 69.14%, p =
0.03) and Dmean (61.38 vs 70.55 Gy, p = 0.03) for SPCM
at 6 months following treatment were statistically signifi-
cant. When compared according the presence of prox-
imal esophageal stricture on VF, the difference in terms
of V70 (1.86 vs 44.44%, p = 0.007), Dmean (64.77 vs
69.55 Gy, p = 0.03) and Dmax (68.18 vs 73.29 Gy, p =
0.02) for MPCM, V70 (12.05 vs 49.74%, p = 0.03) and
Dmax (67.23 vs 73.08 Gy, p = 0.05) for IPCM and Dmax
(70.95 vs 75.65 Gy, p = 0.04) for larynx at 3 months fol-
lowing treatment and in terms of V65 (32.90 vs 91.70%,
p = 0.02), V70 (2.12 vs 35.55%, p = 0.04), Dmean (64.34 vs
69.18 Gy, p = 0.02) and Dmax (67.97 vs 72.56 Gy, p =
0.03) for MPCM at 6 months following treatment were
statistically significant.
For patients not receiving chemotherapy, when com-
pared according the presence of impaired lingual move-
ment on VF, the difference in terms of V70 (15.54 vs
86.78%, p = 0.06) for MPCM, V70 (0.33 vs 16.39%, p =
0.02) and Dmean (61.94 vs 69.37 Gy, p = 0.05) for IPCM
and V70 (17.00 vs 97.00%, p = 0.05), Dmean (66.29 vs
73.52 Gy, p = 0.05) and Dmax (71.24 vs 77.56 Gy, p = 0.05)
for larynx at 6 months following treatment were statisti-
cally significant. When compared according the presence
of BOT weakness on VF, the difference in terms of Dmean
(59.93 vs 66.12 Gy, p = 0.05) for IPCM and Dmax (53.32 vs
63.58 Gy, p = 0.03) for PES at 6 months following treat-
ment were statistically significant.
Dose-volume data correlated with QoL scores
At 3 months following treatment, QoL scores for HNSO
were positively correlated with V60 (p = 0.05, r = 0.44),
Dmean (p = 0.03, r = 0.48) and Dmax for SPCM (p = 0.01, r =
0.54). At 6 months following treatment, QoL scores for
HNPA were positively correlated with V70 for SPCM (p =
0.02, r = 0.51) and V65 (p = 0.04, r = 0.46) and V70 (p = 0.03,
r = 0.50) for PCM and QoL scores for HNSO were posi-
tively correlated with V60 (p = 0.01, r = 0.56), V65 (p = 0.002,
r = 0.65), V70 (p = 0.005, r = 0.60), Dmean (p = 0.008, r = 0.57)
and Dmax for SPCM (p = 0.002, r= 0.65) and V60 (p = 0.02,
r = 0.50), V65 (p = 0.01, r = 0.55), V70 (p = 0.03, r = 0.50) and
Dmean for PCM (p = 0.02, r = 0.51).
For patients with nasopharyngeal primaries, at 3 months
following treatment, QoL scores for HNPA were positively
correlated with V70 (p = 0.03, r = 0.69) and Dmean (p =
0.005, r = 0.81) for PCM and QoL scores for HNSW were
positively correlated with Dmean (p = 0.03, r = 0.68) for
BOT. At 6 months following treatment, QoL scores for
QL were negatively correlated with Dmax for PCM (p =
0.04, r = −0.66) and Dmax for SPCM (p = 0.04, r = −0.67)
and QoL scores for HNPA were positively correlated with
V70 (p = 0.05, r = 0.64) and Dmean (p = 0.01, r = 0.76)
for PCM.
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lowing treatment, QoL scores for HNSO were positively
correlated with Dmax for SPCM (p = 0.04, r = 0.65).
For patients receiving chemotherapy, at 3 months fol-
lowing treatment, QoL scores for HNPA were positively
correlated with V70 (p = 0.03, r = 0.62) and Dmean (p =
0.04, r = 0.60) for PCM and QoL scores for HNSO were
positively correlated with Dmax for SPCM (p = 0.002, r =
0.80). At 6 months following treatment, QoL scores for
QL were negatively correlated with Dmax for PCM (p =
0.03, r = −0.62) and Dmax for BOT (p = 0.009, r = −0.72),
QoL scores for HNPA were positively correlated with
V70 (p = 0.01, r = 0.70) and Dmean (p = 0.03, r = 0.62) for
PCM and V70 (p = 0.03, r = 0.62) for SPCM, QoL scores
for HNSW were positively correlated with V70 (p = 0.01,
r = 0.69) for PCM, V70 (p = 0.03, r = 0.64) for SPCM and
Dmax for BOT (p = 0.05, r = 0.59) and QoL scores for
HNSO were positively correlated with V70 (p = 0.02, r =
0.66) and Dmax for PCM (p = 0.05, r = 0.56), V65 (p = 0.02,
r = 0.65), V70 (p = 0.009, r = 0.72) and Dmax (p = 0.002, r =
0.79) for SPCM and Dmax for BOT (p = 0.004, r = 0.76).
VF findings correlated with QoL scores
When compared according the presence of VF findings,
the difference in terms of the QoL scores before treat-
ment, at 3 months following treatment and at 6 months
following treatment were not statistically significant.
For patients with laryngeal primaries, when compared
according the presence of penetration on VF, the differ-
ence in terms QoL scores for QL (68.75 vs 25.00, p = 0.04)
before treatment and in terms of QoL scores for HNSO (0
vs 26.5, p = 0.05) at 6 months following treatment were
statistically significant. When compared according the
presence of aspiration on VF, the difference in terms QoL
scores for QL (69.88 vs 46.00, p = 0.05) at 6 months
following treatment were statistically significant.
For patients receiving chemotherapy, when compared
according the presence of reduced epiglottic inversion
on VF, the difference in terms QoL scores for HNSW
(25 vs 50.33, p = 0.03) at 6 months following treatment
were statistically significant.
For patients not receiving chemotherapy, when com-
pared according the presence of reduced epiglottic inver-
sion on VF, the difference in terms QoL scores for QL
(69.33 vs 29.50, p = 0.04) at 6 months following treatment
was statistically significant. When compared according the
presence of aspiration on VF, the difference in terms
QoL scores for QL (69.33 vs 29.50, p = 0.04) at 6 months
following treatment was statistically significant.
Discussion
Strong evidence suggests that the intensification of radi-
ation therapy for HNC should result in improved local
control and survival. However, such intensification wouldnot be achievable, even through the use of highly con-
formal radiation therapy techniques, unless the necessary
measures are undertaken in attempt to prevent potentially
serious treatment related toxicity, most notably in the
form of xerostomia and dysphagia [10]. At present, certain
measures to reduce the incidence and severity of xerosto-
mia have been successfully implemented into treatment
regimens. However, the same does not apply to dysphagia.
Hence, dysphagia appears to be arguably the biggest
challenge towards further improving the therapeutic index
for definitive radiation therapy for HNC [11].
The prevalence of dysphagia in patients receiving defini-
tive radiation therapy for HNC appears to be quite high.
Dysphagia might interfere with the nutritional status (lead-
ing to gastrostomy tube dependence or a need for esopha-
geal dilatation), compromise the QoL (leading to anxiety
and/or depression) and even result in life-threatening com-
plications such as aspiration-related pneumonia [1,5]. Any
successful attempt at the reduction of the incidence and
the severity of radiation therapy related dysphagia should
rely on the physiology of swallowing as well as the clinical
and the dosimetric determinants of dysphagia [12]. The
complex process of swallowing includes the conscious ef-
fort of food ingestion and the subconscious efforts of bolus
preparation in the oral cavity and bolus transportation
from the pharynx through the esophagus. Swallowing
requires the intricate coordination of numerous muscles of
the oral cavity, the pharynx, the larynx and the esophagus.
In the oral preparatory phase, the tongue helps mixing the
food and moving it towards the teeth while the soft palate
creates a seal to prevent premature spillage in to the
pharynx. The tongue then contracts from the anterior to
the posterior, pushing the bolus into the pharynx. In the
pharyngeal phase, the soft palate closes the nasopharynx as
the larynx is elevated and closed, the PCMs are contracted
and the CM is relaxed. The true cords, the false cords, the
epiglottis and the aryepiglottic folds constrict to form a
barrier to prevent aspiration. When the larynx is elevated
superiorly and anteriorly and the CM is relaxed, the result-
ant negative pressure in the proximal esophagus helps the
movement of the bolus. The laryngeal inlet is closed
through the elevation of the larynx as well as the pressure
exerted by the BOT and bolus itself. In the esophageal
phase, a single primary peristaltic wave and several second-
ary peristaltic waves help to clear the residue and any
gastric reflux [13].
Radiation therapy might result in functional impair-
ments involving the entire time frame describing swal-
lowing, such as reduced oromotor control and delayed
or absent reflexes prior to swallowing, reduced laryngeal
closure, reduced epiglottic inversion or reduced laryn-
geal elevation during swallowing and reduced pharyngeal
peristalsis, CM dysfunction and structural abnormalities
following swallowing [14]. The outcome might be a
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posterior movement of the BOT regarding the oral
phase and the pharyngeal phase, laryngeal incompetence
and resultant aspiration regarding the pharyngeal phase
and the esophageal phase or the development of an
esophageal stricture regarding the esophageal phase
[15,16]. Despite the complexity in defining the most im-
portant anatomical structures (such as the BOT, the lar-
ynx and the PES) and sub-structures (such as the SPCM,
the MPCM and the IPCM) whose damage would be the
likely cause of dysphagia and the relative paucity in
evaluating the associated dose-volume data, dysphagia in
relation to dosimetric parameters has been the subject
of recent research by many investigators [17,18].
Although a number of studies that evaluated various
dysphagia-related endpoints (such as the objective VF
findings or the subjective QoL scores) in relation to the
dose-volume data for the dysphagia-related anatomical
structures (such as the larynx and the pharynx) were
reviewed for the Quantitative Analysis of Normal Tissue
Effects in the Clinic (QUANTEC), the data from these
studies that was used to produce the recommended dose
versus volume limits for the larynx and the pharynx
mainly apply to patients treated either with 3DCRT or
with intensity-modulated radiation therapy (IMRT) not
aimed at sparing the dysphagia-related anatomical struc-
tures [19]. As a consequence, drawing strict dose versus
volume constraints or volume effect parameters from
these studies were hampered by the fact that high doses
had already been delivered to these structures. Jensen
et al. used EORTC QoL questionnaires as the subjective
means and FEES as the objective means to describe
swallowing function following 3DCRT and attempted to
correlate swallowing function with irradiated volumes.
Subjective swallowing complaints were present in 83% of
the patients whereas 100% of the patients had abnormal
FEES findings, most common of which were residuals,
penetration, aspiration and decreased sensitivity. Corre-
lations were observed between subjective and objective
measures of swallowing dysfunction and the dosimetric
parameters of dysphagia-related anatomical structures.
Doses less than 60 Gy to the supraglottic larynx and the
PES were associated with a lower risk of aspiration [20].
Levendag et al. reported on the use of multiple QoL in-
struments to objectively evaluate the long-term effects of
radiation therapy on the swallowing apparatus on 81 pa-
tients with oropharyngeal cancer treated with 3DCRT or
IMRT. The probability of patient-rated swallowing com-
plaints was correlated with the Dmean for the SPCM and
the Dmean for the MPCM. Since a sharp increase (of ap-
proximately 18%) was observed in patient-rated swallow-
ing complaints per 10 Gy of dose beyond the Dmean of
55 Gy, constraining the dose to be received by the swal-
lowing muscles was proposed as a means of improving theQoL [7]. Feng et al. prospectively evaluated dysphagia in
patients with oropharyngeal cancer and nasopharyngeal
cancer prior to and at 3 months following IMRT for
VF-based objective endpoints, patient-reported subjective
endpoints and observer-rated subjective endpoints. The
Dmean for the PCMs and the Dmean for the glottic and the
supraglottic larynx were correlated with the objective find-
ing of aspiration on VF, the Dmean for the PCMs and the
Dmean for the esophagus were correlated with the subject-
ive finding of worsened liquid swallowing on patient-
reported questionnaires and the Dmean for the PCMs was
correlated with the subjective finding of worsened solid
swallowing on both patient-reported questionnaires and
observer-rated toxicity scoring [5]. In the present study,
dysphagia was prospectively evaluated in patients with
nasopharyngeal cancer and supraglottic laryngeal cancer
prior to 3DCRT, at 3 months following 3DCRT and at
6 months following 3DCRTusing bothVF-based objective
endpoints and patient-reported subjective endpoints. On
objective evaluation, the Dmax for the larynx and the sub-
structures of the PCM were correlated with impaired lin-
gual movement, BOT weakness and proximal esophageal
stricture at 3 months following treatment, whereas the
V65, the V70and the Dmax for the larynx was correlated
with BOT weakness and the V65, the V70, the Dmax or the
Dmean for the sub-structures of the PCM were correlated
with impaired lingual movement, BOT weakness, reduced
laryngeal elevation, reduced epiglottic inversion and aspir-
ation at 6 months following treatment. On subjective evalu-
ation, the V60, the Dmax and the Dmean for SPCM were
correlated with QoL scores for HNSO at 3 months follow-
ing treatment, whereas the V70 for SPCM were correlated
with QoL scores for HNPA and the V60, the V65, the V70,
the Dmax and the Dmean for SPCM were correlated with
QoL scores for HNSO at 6 months following treatment.
Conclusion
In most of the studies that attempt to correlate the object-
ive VF findings and the subjective QoL scores, there are dis-
crepancies in terms of the dysphagia-related endpoints in
relation to the dose-volume data for the dysphagia-related
anatomical structures. A possible cause of the discrepancy
might be the variations in terms of the methods used in the
assessment of dysphagia, ranging from objective means
such as aspiration-related radiological imaging and feeding
tube dependency to subjective means such as patient-
reported questionnaires or observer-reported scales. An-
other possible cause of the discrepancy might be the pa-
tients’ lack of appreciation of certain functional swallowing
abnormalities, despite these abnormalities being clinically
relevant, and the shifts observed over time in the patients’
responses regarding the subjective endpoints, representing
either a true functional improvement or the patients’ ac-
commodation to their new functional status. Therefore, the
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http://www.ro-journal.com/content/9/1/137use of multiple dysphagia-related endpoints to complement
each other rather than to overlap with one another, as well
as the use of multiple evaluations over time to represent a
scale of early to late findings might provide a better insight
in terms of the association of the clinical correlates of dys-
phagia with the dose-volume data for the dysphagia-related
anatomical structures.
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